Identification of novel Th17 inducing CTLR agonists for vaccines against mycobacterium tuberculosis

佐剂发现计划支持新的候选疫苗佐剂的早期发现和初步表征。这项研究必须包括：(1)通过高通量筛选方法确定新的候选佐剂并验证先导化合物刺激人体细胞的作用；(2)确定选定的先导化合物的作用机制，包括确定候选佐剂所通过的受体(S)及其激活的细胞信号通路；(3)以构效关系研究为指导，通过配方和药物化学方法优化候选先导佐剂；(4)在动物模型中验证先导化合物作为疫苗佐剂的有效性。 项目必须包括动物模型研究，以测试候选佐剂疫苗对以下疾病的影响： A)一种或多种新出现和再次出现的传染病病原体http://www.niaid.nih.gov/topics/emerging/pages/default.aspx)，或 B)一个或多个NIAID新出现和再次出现的传染病病原体以及一个或多个与人类疾病有关的其他(非艾滋病毒)病原体。

The Adjuvant Discovery Program supports the early stage discovery and initial characterization of novel vaccine adjuvant candidates. The research must include (1) identification of novel adjuvant candidates through high throughput screening (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the mechanism of action of select lead compounds, including the identification of the receptor(s) the adjuvant candidates work through and the cellular signaling pathways they activate; (3) optimization of lead adjuvant candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model. Projects must include animal model studies to test the adjuvant candidates with vaccines against: A) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens http://www.niaid.nih.gov/topics/emerging/pages/default.aspx), or B) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens as well as one or more other (non-HIV) pathogens relevant to human disease.